Sub analyses of CANTOS trial of canakinumab announced as a treatment for CV risk. - Novartis.

Novartis announces two subanalyses from the CANTOS trial which suggest that canakinumab may be a therapy for the highest cardiovascular risk patients. In the two analyses�one in patients with chronic kidney disease and the other in diabetes�canakinumab "substantially" reduced the risk of major adverse cardiovascular events, Brigham and Women's Hospital researchers said at the American College of Cardiology conference in Orlando. Both groups of patients are at higher risk of heart attack, stroke and other cardiovascular complications.

In chronic kidney disease patients, canakinumab reduced the risk of events by 18% over placebo. For patients with diabetes, canakinumab cut risks by 10% in a composite measure of CV events, known as MACE, while those with prediabetes experienced a 14% risk reduction.